March 4 (Reuters) - Contineum Therapeutics Inc CTNM.O:
CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1B CHRONIC PAIN TRIAL OF PIPE-791
CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 PHASE 1B TRIAL EXPECTED IN EARLY 2026
Source text: ID:nBwbMmCNpa
Further company coverage: CTNM.O
((Reuters.Briefs@thomsonreuters.com;))